Fuzionaire Radioisotope Technologies (FRIT) and radiopharmaceutical firm Nihon Medi-Physics (NMP) are teaming up in a bid to create a new class of PET radiopharmaceuticals.
NMP, a joint venture between Sumitomo Chemical Company and GE Healthcare, will assess the ability of Fuzionaire's F-18 radiolabeling platform in a feasibility study. Fuzionaire aims to apply its technology to create new radiopharmaceuticals that can aid in predicting and measuring patient response to cancer immunotherapy treatments, according to the companies.
Formed in 2019 as a joint venture of Fuzionaire Diagnostics and Japan Medical Isotope Technology Development, FRIT is working to develop and commercialize Fuzionare Dx's radiopharmaceutical technologies in Japan.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
